RxDoctor Payments Data

Emmanuel Tuffuor, MD

Internal Medicine · Warrensville Heights, OHNPI 1063449353

Payments from drug & device makers

$3,696in general payments, 2019–2025

Across 101 payments — averaging $36.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$814
  • Pfizer$382
  • GSK$279
  • Novartis$225
  • Olympus America Inc.$158
  • plus $660 from 11 others

What the payments were for

  • Food & beverage$3,64299%
  • Education$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,696 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$37,801
Medicare patients
97
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$40,230
OzempicSemaglutide34$35,200
EntrestoSacubitril/Valsartan15$25,117
MounjaroTirzepatide17$21,264
FarxigaDapagliflozin Propanediol18$18,965
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,692
JanuviaSitagliptin Phosphate15$10,228
LinzessLinaclotide18$9,367
Albuterol Sulfate HfaAlbuterol Sulfate102$2,799
Atorvastatin Calcium196$2,332
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,589
Rosuvastatin Calcium75$1,306
Losartan Potassium86$1,236
Gabapentin85$1,106
Amlodipine Besylate197$1,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$382$40,23047 claims
Novo NordiskOzempic$1,177$35,20034 claims
NovartisEntresto$225$25,11715 claims
AstraZenecaFarxiga$814$18,96518 claims
GSKTrelegy Ellipta$279$14,69220 claims
AbbVieLinzess$17$9,36718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Warrensville Heights

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →